Allergan (AGN) Given a $250.00 Price Target at UBS Group

UBS Group set a $250.00 price objective on Allergan (NYSE:AGN) in a research report released on Wednesday, January 10th, www.tipranks.com reports. The brokerage currently has a buy rating on the stock.

A number of other brokerages have also issued reports on AGN. Deutsche Bank reissued a buy rating and set a $262.00 price target on shares of Allergan in a research note on Tuesday, September 12th. Citigroup restated a buy rating and set a $280.00 price objective on shares of Allergan in a report on Wednesday, September 20th. Morgan Stanley downgraded Allergan from an overweight rating to an equal weight rating and reduced their price objective for the stock from $284.00 to $228.00 in a report on Wednesday, September 20th. Cantor Fitzgerald restated a hold rating and set a $231.00 price objective on shares of Allergan in a report on Friday, September 22nd. Finally, Piper Jaffray Companies set a $227.00 price objective on Allergan and gave the stock a hold rating in a report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the stock. Allergan currently has an average rating of Buy and an average target price of $227.56.

Allergan (NYSE:AGN) traded down $6.03 during trading hours on Wednesday, hitting $172.51. The stock had a trading volume of 3,387,933 shares, compared to its average volume of 2,650,000. The company has a market cap of $59,380.00, a price-to-earnings ratio of -7.64, a price-to-earnings-growth ratio of 1.32 and a beta of 1.19. Allergan has a 1-year low of $160.07 and a 1-year high of $256.80. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08.

Allergan (NYSE:AGN) last posted its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.06 by $0.09. Allergan had a positive return on equity of 8.00% and a negative net margin of 47.27%. The business had revenue of $4.03 billion during the quarter, compared to analyst estimates of $4.04 billion. During the same period last year, the company earned $3.32 EPS. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. analysts expect that Allergan will post 16.27 earnings per share for the current year.

In other news, insider William Meury sold 11,807 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $173.89, for a total value of $2,053,119.23. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Brent L. Saunders acquired 4,600 shares of the firm’s stock in a transaction dated Wednesday, December 6th. The stock was bought at an average cost of $164.74 per share, with a total value of $757,804.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 17,630 shares of company stock valued at $2,890,057. 0.36% of the stock is currently owned by insiders.

Institutional investors have recently made changes to their positions in the stock. Pathstone Family Office LLC increased its stake in Allergan by 3,327.3% during the 2nd quarter. Pathstone Family Office LLC now owns 377 shares of the company’s stock worth $2,035,000 after buying an additional 366 shares in the last quarter. Howard Hughes Medical Institute purchased a new stake in Allergan during the 2nd quarter worth approximately $103,000. Massey Quick & Co. LLC increased its stake in Allergan by 334.8% during the 2nd quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock worth $122,000 after buying an additional 385 shares in the last quarter. Cable Hill Partners LLC increased its stake in Allergan by 255.2% during the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after buying an additional 370 shares in the last quarter. Finally, Pacific Center for Financial Services increased its stake in Allergan by 1.3% during the 2nd quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock worth $132,000 after buying an additional 7 shares in the last quarter. Hedge funds and other institutional investors own 81.21% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/03/allergan-agn-given-a-250-00-price-target-by-ubs-group-analysts.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply